Clinical trial NCT00696956: Drug Coated Balloons for Prevention of Restenosis
Official title: Paclitaxel Coated Balloons for Prevention of Restenosis in Small Arteries Below the Knee Compared to Angioplasty Using Uncoated Balloons
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Atherosclerosis
Restenosis
Limb Ishemia
Keywords: local drug delivery
balloon angioplasty
safety and tolerance of paclitaxel coated PTA balloons
in inhibiting restenosis of below the knee arteries
Efficacy of paclitaxel coated PTA balloons
in inhibiting restenosis of below the knee arteries (late lumen loss)
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
First posted: 2008-06-13
Enrollment: 114
Sex: ALL
Minimum age (years): 18
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will be performed as a randomized, double blind trial (in respect of the primary end point) with treatment of the stenotic lesion using uncoated PTA-catheters as control group. 114 patients will be included in the trial at about 5 study centers. Follow-up includes control angiography after 6 and 18 months and clinical follow-up examinations up to 18 months. Primary objective:

Efficacy of paclitaxel coated PTA balloons in inhibiting restenosis of below the knee arteries (late lumen loss)

Secondary objective:

Various angiographic and clinical efficacy measures, safety and tolerance of pacli-taxel coated PTA balloons in inhibiting restenosis of below the knee arteries Descriptive statistics, comparison by t-test, chi-square test for binary events 10.1 Descriptive statistics As far as applicable descriptive statistics will be applied to data and will be referring to individual changes versus baseline (predilatation or immediately postdilatation). The groups will be compared to each other testing the statistical significance of differences (p ≤ 0.05). Con-tinuous data will be expressed as mean ± standard deviation.

Categorical variables will be compared using the chi-squared test, and continuous variables will be compared using Student's t test or ANOVA analysis.

In addition to the assessment of the primary endpoint and the secondary endpoints a multi-variate analysis to investigate the influence of risk factors on the interventional outcome (interventional success, early restenosis/occlusion, LLL, stent integrity) and clinical outcomes will be performed. For this analysis the following factors will be considered: age, diabetes, neurological status (only Rutherford 5), lesion length, grade of dissection and calcification, reststenosis, number of run-off vessels, stent administration in the index lesion(s).

10.2 Estimated number of patients The primary endpoint of the study is late lumen loss (LLL) at 6 months evaluated by quantitative angiography. Because no data according this endpoint are available for both the control group and the group which will be treated with the paclitaxel coated balloon an assumption according the LLL at 6 months was made according the expectations of the principle investigator. An estimate for LLL as % of MLD in the control group is 50% and in the drug coated balloon group 30 %. The standard deviation is calculated to be 30% of LLL. A sample size of 37 patients in each group will allow the detection of a statistically significant difference (p\<0.05) with 80% power. Based on the "Below study" which enrolled patients with comparable arterial lesions in Tuebingen and the data of the Basil study, it is estimated that 35% of the patients who will be enrolled in the study will not be available for follow-up investigations in order to calculate the MLD.

In order to meet a statistical endpoint a total of 114 patients will be enrolled.


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 95 years,
* peripheral vascular disease, Rutherford stage 3-5, diameter stenosis ≥ 70 %, ≥ 15 -150 mm length, up to 2 vessels to be treated

Exclusion Criteria:

* Disease associated with life-expectancy less than 18 months
* Acute thrombus or aneurysm in the index limb/ vessel
* Doubts in the willingness or capability of the patient to allow follow up examination

Primary outcomes:
measure: Primary endpoint: Late lumen loss (LLL) of the target lesion after 6 months (assessed by DSA)
timeFrame: after 6 months
Secondary outcomes:
measure: Interventional success rate (defined as reststenosis less than 50%)
timeFrame: up to 18 months
measure: Restenosis rate at 6 and 18 months (restenosis rate is defined as a diameter stenosis of ≥ 50% of reference diameter
timeFrame: up to 18 months
measure: Minimum lumen diameter (MLD) at 6 months
timeFrame: up to 18 months
measure: Target lesion revascularization recorded at 6, 12 and 18 months; target lesion revascularization is defined as any reintervention or artery bypass graft surgery involving the target lesion.
timeFrame: up to 18 months
measure: Target vessel revascularization recorded at 6, 12 and 18 months
timeFrame: up to 18 months
measure: Target limb revascularization recorded at 6, 12 and 18 months
timeFrame: up to 18 months
measure: Improvement of clinical stage at 6, 12 and 18 months
timeFrame: up to 18 months
measure: Change in ABI compared to pretreatment if vessels are compressible
timeFrame: up to 18 months
measure: Hospitalization (extra days due to complications of the index procedure) and hospitalization between the follow-up visits due to the index leg
timeFrame: up to 18 months
measure: Major amputations at the index limb
timeFrame: up to 18 months
measure: Mortality
timeFrame: up to 18 months
measure: LLL of stented segments at 6 months comparing the uncoated and the coated bal-loon group.
timeFrame: up to 18 months
measure: Subgroup analysis; primary endpoint and TLR
timeFrame: up to 18 months
measure: LLL, MLD and restenosis rate at 18 month follow-up determined by angiography
timeFrame: up to 18 months
measure: Subgroup analysis neuropathy and no neuropathy according to clinical improve-ment in patients classified Rutherford 5
timeFrame: up to 18 months
measure: Clinical benefit patients Rutherford 3 vs. Rutherford 4 and 5
timeFrame: up to 18 months
Other outcomes:
Locations:
city: Bad Krozingen
country: Germany
facility: Herzzentrum Bad Krozingen
state: BW
city: Tuebingen
country: Germany
facility: University of Tuebingen
state: BW
city: Berlin
country: Germany
facility: Charite Berlin
state: B
city: Berlin
country: Germany
facility: Jüdisches Krankenhaus Berlin
state: B
city: Rostock
country: Germany
facility: University of Rostock
state: MP
Study officials:
References:
citation: Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008 Feb 14;358(7):689-99. doi: 10.1056/NEJMoa0706356.